Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials

The MODIFY I/II trials demonstrated that bezlotoxumab, a human monoclonal antibody against Clostridioides difficile toxin B, given during antibiotic treatment for Clostridioides difficile infection (CDI) significantly reduced C. difficile recurrence (rCDI) in adults at high risk for rCDI. Efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouza, Emilio, Cornely, Oliver A., Ramos-Martinez, Antonio, Plesniak, Robert, Ellison, Misoo C., Hanson, Mary E., Dorr, Mary Beth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497347/
https://www.ncbi.nlm.nih.gov/pubmed/32504314
http://dx.doi.org/10.1007/s10096-020-03935-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497347/
https://www.ncbi.nlm.nih.gov/pubmed/32504314
http://dx.doi.org/10.1007/s10096-020-03935-3

Ejemplares similares